Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn’s Disease: A Post Hoc Analysis of the REACH Trial

Citation:

Cheifetz AS, Vande Casteele N, Wang Z, et al. Am J Gastroenterol. 2023 Mar 1;118(3):485-490. Epub 2022 Dec 23. PMID: 36624036; PMCID: PMC9991960.